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T
here is great excitement in the 
tuberculosis (TB) scientific 
community over the introduction 
of new tools into TB control activities. 
The development of new tools is an 
important component of the Global 
Plan to Stop TB and the World 
Health Organization’s new global 
Stop TB Strategy [1,2]. Anticipating 
the introduction of new tools, the 
Stop TB Partnership has established 
a Retooling Task Force to develop a 
framework for engaging policy makers 
to foster accelerated adoption and 
implementation of new tools into TB 
control programs [3].
While new tools offer great promise 
in clinical medicine and in public 
health, limited resources and the 
movement toward evidence-based 
guidelines and policies require careful 
validation of new tools prior to their 
introduction for routine use. The 
world spends an estimated US$1 
billion per year on diagnostics for 
TB [4]. It is important to ensure that 
such expenditure is backed by strong 
evidence. 
Ideally, clinical and policy decisions 
must be guided by the totality of 
evidence on a given topic. This is 
particularly relevant for TB, where 
concerns have been raised about 
the lack of emphasis on evidence of 
effectiveness in some of the existing 
TB guidelines and policies [5]. 
These concerns are being taken 
seriously [6,7], and the outcome 
should be evident in upcoming TB 
guidelines and policies. In fact, the 
World Health Organization (WHO) 
recently announced its approach 
for developing new policies on TB 
in a document entitled “Moving 
Research Findings into New WHO 
Policies” [7]. According to this 
document, in order to consider a 
global policy change, WHO must 
have solid evidence, including 
clinical trials or field evaluations in 
high TB prevalence settings. The 
steps involved in the policy process 
include a comprehensive review of the 
evidence, as well as expert opinion 
and judgment (Box 1).
High-quality evidence on TB 
diagnostics is critical for the 
development of evidence-based policies 
on TB diagnosis, and, ultimately, for 
effective control of the global TB 
epidemic. While primary diagnostic 
trials are needed to generate data 
on test accuracy and operational 
performance, systematic reviews provide 
the best synthesis of current evidence on 
any given diagnostic test [8]. Although a 
large number of trials on TB diagnostics 
have been published, surprisingly, no 
systematic reviews were published until 
recently. In the past few years, at least 
30 systematic reviews and meta-analyses 
have been published on various TB tests 
[9–38]. These reviews have synthesized 
the results of more than 1,000 primary 
studies, providing valuable insights into 
the diagnostic accuracy of various tests 
(Table 1, Box 2).
Implications for Clinical and 
Laboratory Practice 
For clinicians, systematic reviews 
provide several useful insights for 
diagnosis of latent TB infection, active 
TB disease, and drug resistance. 
For diagnosis of latent TB, 
clinicians have used the tuberculin 
skin test (TST) for decades. Recently, 
interferon-gamma release assays 
(IGRAs) have emerged as attractive 
alternatives. While the TST is known 
to have poor specificity in populations 
vaccinated with bacille Calmette-
Guérin (BCG) [34], meta-analyses have 
shown that IGRAs have much higher 
specificity for TB infection than the 
TST, and IGRA specificity is unaffected 
by BCG vaccination [21,26,37]. 
However, another meta-analysis 
showed that BCG vaccination received 
in infancy has a minimal effect on 
the TST, whereas BCG received after 
infancy produces more frequent, more 
persistent, and larger TST reactions 
[35]. Thus, the TST might retain 
high specificity in some populations, 
whereas it may perform poorly in 
others. IGRAs are particularly attractive 
in the latter setting. However, meta-
analyses on IGRAs have highlighted 
the lack of evidence on the predictive 
ability of these assays in identifying 
those individuals with TB infection who 
are at highest risk for progressing to 
active disease. Several cohort studies 
are ongoing (reviewed elsewhere 
[39]), and these should provide useful 
evidence on this unresolved issue.
For active TB, serological tests have 
been attempted for decades. Two 
meta-analyses have convincingly shown 
that existing commercial antibody-
based tests have poor accuracy and 
limited clinical utility [29,30]. Despite 
this evidence, dozens of commercial 
serological tests continue to be 
marketed, mostly in private sectors 
of countries that lack diagnostic 
regulatory bodies [4].
Nucleic acid amplification tests 
(NAATs) were considered to be a 
major breakthrough in TB diagnosis 
when they were first introduced. A 
series of meta-analyses have shown 
that NAATs have high specificity and 
positive predictive value, but modest 
and highly variable sensitivity, especially 
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in smear-negative and extrapulmonary 
TB [9,11,14,18,23,24,28].
Conventional tests such as smears 
and cultures perform poorly in 
extrapulmonary TB. A series of 
reviews have shown that biomarkers 
such as adenosine deaminase (ADA) 
and interferon-gamma (IFN-γ) have 
excellent accuracy for tuberculous 
pleural effusion [12,13,15,17]. These 
biomarkers, especially ADA, are easy 
to measure and inexpensive. Despite 
this evidence, these tests appear to be 
underutilized [40].
For the diagnosis of multidrug-
resistant TB (MDR-TB), available 
data suggest that phage-based assays 
do not perform well when directly 
applied to clinical specimens [25]. 
Line probe assays show great promise 
for rapid detection of rifampicin 
resistance in settings with high MDR-
TB prevalence [22,38]. Simple tests 
such as colorimetric redox methods 
and nitrate reductase assays appear to 
perform very well, but require culture 
isolation [19,36]. More evidence 
is needed on rapid tests for drug 
resistance, especially since the Global 
XDR-TB Response Plan calls for wide-
scale implementation of rapid methods 
to screen patients at risk of XDR-TB 
(extensively drug-resistant TB) and 
MDR-TB [41].
For laboratory practice, systematic 
reviews provide strong evidence that 
fluorescence microscopy is more 
sensitive than conventional light 
microscopy (with no significant loss 
in specificity) [31], that sputum 
processing methods (e.g., bleach 
or centrifugation) can be effective 
in increasing the yield of smear 
microscopy [32], and that liquid 
cultures are more rapid and sensitive 
than solid cultures [10].
Implications for Policies and 
Guidelines
In addition to informing evidence-
based TB diagnosis, systematic reviews 
have been helpful in informing policy 
decisions. For example, a series of 
recent reviews has shown that smear 
microscopy can be optimized using 
at least three different approaches: 
chemical and physical processing 
for concentration of sputum, use of 
fluorescence microscopy instead of 
conventional light microscopy, and the 
examination of two (as compared to 
three) sputum specimens [20,31,32]. 
The findings of these reviews were 
incorporated into the International 
Standards for TB Care [42], and 
have informed policy guidance on 
the diagnosis of smear-negative TB in 
people living with HIV/AIDS [43].
The review on incremental yield of 
serial smears showed that the average 
incremental yield and/or increase 
in sensitivity of examining a third 
sputum specimen ranged between 
2% and 5% [20]. This suggested that 
reducing the recommended number of 
specimens examined from three to two 
could potentially benefit TB control 
programs, and potentially increase 
case detection for several reasons [20]. 
Partly based on this evidence and 
expert opinion, WHO recently revised 
its policies on smear microscopy [44]. 
It now recommends that the number 
of specimens to be examined for 
screening of TB cases be reduced from 
three to two, in places where a well-
functioning external quality assurance 
system exists, where the workload is 
very high, and where human resources 
are limited [44]. The revised WHO 
definition of a new sputum smear-
positive pulmonary TB case is based on 
the presence of at least one acid fast 
bacillus in at least one sputum sample 
in countries with a well-functioning 
external quality assurance system [45]. 
These new policies have major 
implications for resource-poor settings 
with high TB prevalence where 
sputum microscopy is the main or 
Box 1. WHO Policy Process for Tuberculosis
1. Identifying the Need for a Policy Change
The need to formulate new or revised policies may arise from WHO’s ongoing 
monitoring of technical developments or from interested parties submitting requests 
with supporting documentation for policy or guideline development. WHO receives 
information about a new technology or approach via many channels, with the most 
direct lines coming from national TB programs and researchers themselves. To 
consider a global policy change, WHO must have solid evidence, including clinical 
trials or field evaluations in high TB prevalence settings.
2. Reviewing the Evidence
WHO may carry out or commission a review of the documentation of the technology’s 
clinical or programmatic performance, including newly published and “grey” research 
or reviews, “proof of principle” reports, large-scale field trials, and demonstration 
projects in different resource settings. Standardized evaluation criteria have been and 
are being developed by the New Diagnostics, New Drugs, and New Vaccines Working 
Groups of the Stop TB Partnership. 
3. Convening an Expert Panel
If the evidence base is compelling, WHO will convene an external panel of experts, 
excluding all original principal investigators from the studies. The panel will review 
the evidence and make a recommendation or propose draft policies or guidelines to 
WHO’s Strategic and Technical Advisory Group for Tuberculosis (STAG-TB). 
4. Assessing Draft Policies and Guidelines
STAG-TB provides objective, ongoing technical and strategic advice to WHO on TB 
care and control. STAG-TB’s objectives are to provide the Director-General, through 
the Stop TB Department, with an independent evaluation of the strategic, scientific, 
and technical aspects of WHO’s TB activities; review progress and challenges in 
WHO’s TB-related core functions; review and make recommendations on committees 
and working groups; and make recommendations on WHO’s TB activity priorities. 
STAG-TB reviews the policy drafts and supporting documentation during its annual 
meeting. STAG-TB may endorse the policy recommendation with or without revisions, 
request additional information and re-review the evidence in subsequent years, or 
reject the recommendation.
5. Formulating and Disseminating Policy
New WHO policies and guidelines will be disseminated through different channels 
to Member States, including through the World Health Assembly, WHO Web site, 
listservs, and journal publications. WHO also disseminates its recommendations to 
other agencies and donors engaged in TB control activities. 
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only diagnostic test available, and 
particularly where laboratory services 
are being overwhelmed with demand 
for smear microscopy. Omitting the 
third smear could potentially reduce 
costs and alleviate the workload of 
laboratories, particularly in countries 
with human resource crises. In these 
settings, laboratories performing 
smear microscopy often have to deal 
with anemia, malaria, and other 
diseases. Thus, the time saved from 
the inefficient examination of a 
third smear may be applied toward 
improving laboratory testing for other 
diseases [20]. The adoption of the 
revised case definition and a two-smear 
approach may create the opportunity to 
examine both smears during a patient’s 
first presentation to a health facility, 
and thereby reduce the large numbers 
of patients known to drop out during 
the diagnostic process [46]. While 
these are reasonable assumptions, it 
is worth emphasizing that there is no 
hard evidence that the two-smear policy 
actually improves TB control in the 
real world. Such data will have to come 
from programmatic research at the 
country level and from data collected in 
routine public health program settings.
There is strong evidence that liquid 
cultures are more sensitive and rapid 
than solid media cultures [10]. Based 
on a review of available evidence 
and an expert consultation, WHO 
recently issued policy guidance on 
the use of liquid TB culture and drug 
susceptibility testing in low-resource 
settings [47]. The WHO policy 
recommends phased implementation 
of liquid culture systems as a part of a 
country-specific comprehensive plan 
for laboratory capacity strengthening 
that addresses issues such as biosafety, 
training, maintenance of infrastructure, 
and reporting of results [47]. These 
policies are expected to have an 
important impact in settings with high 
HIV prevalence [43] and in countries 
where MDR-TB is an increasing 
problem [41], helping to inform the 
needed global scale-up of culture and 
drug susceptibility testing capacity. 
However, implementation of culture 
testing requires a well-functioning 
health care system, adequate laboratory 
infrastructure, and trained personnel. 
Therefore, emphasis must be placed 
on capacity building and health 
system and laboratory strengthening 
[43,48]. Recognizing this, the Stop 
TB Partnership, WHO, and partners 
have launched a Global Laboratory 
Initiative to facilitate laboratory policy 
guidance, technical assistance, quality 
management, resource mobilization, 
and advocacy. Again, as in the case 
of the two-smear strategy, it must be 
emphasized that there is no strong 
evidence that the WHO policy on liquid 
cultures actually improves TB control at 
the routine programmatic level. Field 
studies and cost-effectiveness data are 
needed to better understand the real 
world implications of this policy.
In June 2008, WHO announced 
a new policy statement, endorsing 
the use of line probe assays for rapid 
screening of patients at risk of MDR-TB 
(http://www.who.int/tb/en/). This 
policy statement was based in part on 
evidence summarized in systematic 
reviews [22,38], expert opinion, and 
results of field demonstration projects. 
The recommended use of line probe 
assays is currently limited to culture 
isolates and direct testing of smear-
positive sputum specimens. Line probe 
assays are not recommended as a 
complete replacement for conventional 
culture and drug susceptibility testing. 
Culture is still required for smear-
negative specimens, and conventional 
drug susceptibility testing is still 
necessary to confirm XDR-TB.
Following this new policy, WHO, 
UNITAID, the Stop TB Partnership, 
and the Foundation for Innovative 
New Diagnostics (FIND) announced a 
new initiative to improve the diagnosis 
and treatment of MDR-TB in resource-
limited settings (http://www.who.int/
tb/features_archive/mdrtb_rapid_
tests/en/index.html). As part of this 
initiative, over the next few years, 16 
countries will begin using rapid tests 
to diagnose MDR-TB, including line 
probe assays. The countries will receive 
specially priced tests through the Stop 
TB Partnership’s Global Drug Facility, 
which provides countries with both 
drugs and diagnostic reagents.
Implications for Research and 
Development
Systematic reviews have been helpful 
in identifying key knowledge gaps 
and defining research agendas. 
For example, based on the smear 
microscopy reviews [20,31,32] and 
expert opinion, the UNICEF/UNDP/
World Bank/WHO Special Programme 
for Research and Training in Tropical 
doi:10.1371/journal.pmed.0050156.g001
Figure 1. Low-Cost LED-Based Fluorescence Microscopy Being Evaluated at a TDR/WHO Trial 
Site in Abuja, Nigeria
Photographer: Andrew Ramsay (Courtesy of TDR, Geneva)PLoS Medicine  |  www.plosmedicine.org 1046 July 2008  |  Volume 5  |  Issue 7  |  e156
Diseases (TDR) recently launched a 
major research program aimed at the 
optimization of smear microscopy 
[49]. Large-scale field studies are 
ongoing in more than ten countries 
on issues such as optimum timing and 
composition of sputum specimen sets; 
use of lower-cost light-emitting diode 
(LED) fluorescence microscopy systems 
(Figure 1); sputum processing methods 
involving bleach digestion; and 
potential for reducing time to diagnosis 
and number of patient visits required 
by examining two specimens on the 
day that the patient first presents. The 
latter can be expected to reduce the 
considerable patient drop-out rates 
during diagnosis that are seen in many 
settings [46].
In parallel, FIND recently forged 
a partnership with Carl Zeiss 
MicroImaging (http://www.zeiss.com/
micro/) to develop an inexpensive, 
robust LED-based microscope that will 
be extensively evaluated for routine use 
in high-burden countries [50].
Systematic reviews on existing 
commercial serological tests and 
NAATs have shown that these assays 
have not performed as well as expected 
[14,18,29,30]. A recent evaluation of 
19 rapid commercial serological tests 
for TB using specimens from the TDR 
TB Specimen Bank confirmed the poor 
accuracy of existing serological tests for 
TB [51]. Such evidence has informed 
several initiatives to improve serological 
assays and NAATs. For example, 
FIND is supporting the development 
and evaluation of newer, improved 
NAATs (Figure 2) [52]. Several groups 
are working on methods to optimize 
serological assays, including the use 
of novel TB-specific antigens, the use 
of antigen combinations, and the 
development of point-of-care tests [52].
Systematic reviews on IGRAs 
have informed the development of 
guidelines and positions statements in 
many countries [53,54,55]. They have 
also facilitated the development of a 
comprehensive research agenda with a 
specific focus on the use of these assays 
in resource-limited settings [56].
Systematic reviews on TB diagnostics 
have revealed deficiencies in the quality 
of TB diagnostic trials. A recent analysis 
of systematic reviews showed that trials 
of TB diagnostics lack methodological 
rigor, and studies are often poorly 
reported [57]. Lack of methodological 
rigor in trials is a cause for concern, 
as it may prove to be a major hurdle 
for effective application of diagnostics 
in TB care and control. Biased results 
from poorly designed trials can lead 
to premature adoption of diagnostics 
that may have little or no benefit. The 
situation is exacerbated by the fact that 
most developing countries have poor 
regulatory mechanisms for licensing 
and post-marketing surveillance of 
diagnostics. For example, dozens 
of commercial serological tests are 
marketed in developing countries, 
despite lack of evidence on their utility 
[29,30,51].
It is clear that efforts are needed 
to improve both methodological 
quality and reporting of TB diagnostic 
trials [57,58]. TDR has developed 
guidelines for researchers on assessing 
the performance and operational 
characteristics of diagnostics for 
infectious diseases [59], and the 
STARD (Standards for Reporting 
doi:10.1371/journal.pmed.0050156.g002
Figure 2. A Simplified NAAT Being Evaluated at a FIND Trial Site in India
Photographer: Ralf Linke (Courtesy of FIND, Geneva)
Box 2. Five Key Papers in the Field
Dinnes et al., 2007 [10]. The most comprehensive systematic review of several rapid 
diagnostic tests for the detection of TB, sponsored by the UK Health Technology 
Assessment Programme.
Mase et al., 2007 [20]. This review on incremental yield of serial smears showed that 
the average incremental yield and/or the increase in sensitivity of examining a third 
sputum specimen ranged between 2% and 5%. This evidence partly informed the new 
WHO policy on smear microscopy.
Menzies et al., 2007 [21]. This meta-analysis showed that IGRAs for TB infection have 
excellent specificity (higher than the conventional TST), and are unaffected by prior BCG 
vaccination. This review also highlighted the key unresolved questions regarding the 
use of these assays in clinical practice. An update to this meta-analysis was published 
recently (Pai et al., 2008 [37]).
Steingart et al., 2007 [30]. This meta-analysis showed that serological tests for TB 
produce highly inconsistent estimates of sensitivity and specificity, and none of the 
currently available commercial assays perform well enough to replace microscopy. 
Several initiatives are now ongoing to develop improved point-of-care immune-based 
rapid tests for TB.
Steingart et al., 2006 [31]. This systematic review reported strong evidence that 
fluorescence microscopy is more sensitive than conventional microscopy. Several 
initiatives are now ongoing to develop simple, low-cost fluorescence microscopy 
systems to optimize smear microscopy.PLoS Medicine  |  www.plosmedicine.org 1047 July 2008  |  Volume 5  |  Issue 7  |  e156
Table 1. Findings from Systematic Reviews on TB Diagnostic Tests
Diagnostic Test [References] Number of Reviews  Disease/Site Major Findings/Results of Systematic Reviews
Diagnosis of active TB
Sputum smear microscopy [20,31,32] 3 Pulmonary TB Fluorescence microscopy is on average 10% more sensitive than  sÈ
conventional microscopy. Specificity of both fluorescence and 
conventional microscopy is similar.
Centrifugation and overnight sedimentation, preceded with  sÈ
any of several chemical methods (including bleach), is more 
sensitive than direct microscopy; specificity is unaffected by 
sputum processing methods. 
When serial sputum specimens are examined, the mean  sÈ
incremental yield and/or increase in sensitivity from examination 
of 3rd sputum specimen ranges between 2% and 5%.
NAATs [9,10,11,14,18,23,24,28] 8 Pulmonary and extrapulmonary TB NAATs have high specificity and positive predictive value.  sÈ
NAATs, however, have relatively lower (and highly variable) 
sensitivity and negative predictive value for all forms of TB, 
especially in smear-negative and extrapulmonary disease.
In-house (“home-brew”) NAATs produce highly inconsistent  sÈ
results as compared to commercial, standardized NAATs.
Commercial serological antibody 
detection tests [10,29,30]
3 Pulmonary and extrapulmonary TB Serological tests for both pulmonary and extrapulmonary  sÈ
TB produce highly inconsistent estimates of sensitivity and 
specificity; none of the assays perform well enough to replace 
microscopy.
ADA [12,13,17,27,33] 5 TB pleuritis, pericarditis, peritonitis Measurement of ADA levels in pleural, pericardial, and ascitic  sÈ
fluid has high sensitivity and specificity for extrapulmonary TB.
IFN-γ [13,15] 2 TB pleuritis Pleural fluid IFN-γ determination is a sensitive and specific test  sÈ
for the diagnosis of TB pleuritis.
Phage amplification assays [16] 1 Pulmonary TB Phage-based assays have high specificity but lower and  sÈ
variable sensitivity. 
Their performance characteristics are similar to sputum  sÈ
microscopy.
Automated liquid cultures [10] 1 Pulmonary TB Automated liquid cultures are more sensitive than solid  sÈ
cultures.
Time to detection is more rapid than solid cultures. sÈ
Diagnosis of latent TB infection
TST [34,35] 2 Latent TB infection Individuals who receive BCG vaccination are more likely to have  sÈ
a positive TST; the effect of BCG on TST results is less after 15 
years; positive TST with indurations of >15 mm are more likely to 
be the result of TB infection than of BCG vaccination.
The effect on TST of BCG received in infancy is minimal,  sÈ
especially 10 years after vaccination. BCG received after infancy 
produces more frequent, more persistent, and larger TST 
reactions. 
Non-tuberculous mycobacterial (NTM) infection is not a  sÈ
clinically important cause of false-positive TST, except in 
populations with a high prevalence of NTM sensitization and a 
very low prevalence of TB infection.
T cell–based IGRAs [21,26,37] 3 Latent TB infection IGRAs have excellent specificity (higher than the TST), and are  sÈ
unaffected by prior BCG vaccination.
Diagnosis of drug-resistant TB
Phage amplification assays [25] 1 Rapid detection of  
rifampicin resistance
When used on culture isolates, phage assays have high  sÈ
sensitivity, but variable and lower specificity. 
In contrast, evidence is lacking on the accuracy of these assays  sÈ
when they are directly applied to sputum specimens.
Line probe assays: INNO-LiPA Rif. TB 
(LiPA) [22] and GenoType MTBDR 
assays [38]
2 Rapid detection of rifampicin 
resistance
LiPA is a highly sensitive and specific test for the detection  sÈ
of rifampicin resistance in culture isolates, with relatively 
lower sensitivity when used directly on clinical specimens. 
s4HEÈ'ENO4YPEÈ-4"$2ÈASSAYSÈHAVEÈEXCELLENTÈSENSITIVITYÈANDÈ
specificity for rifampicin resistance even when directly used on 
clinical specimens.
Colorimetric redox-indicator methods 
[19] and nitrate reductase assays [36]
2 Rapid detection of rifampicin and 
isoniazid resistance
Colorimetric methods and nitrate reductase assays are highly  sÈ
sensitive and specific for the rapid detection of rifampicin and 
isoniazid resistance in culture isolates.
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Diagnostic Accuracy) initiative was 
launched to improve the quality of 
reporting of diagnostic studies [60].
Conclusions
With the publication of several 
systematic reviews, there is now a strong 
evidence base to support global policy 
on TB diagnostics. A key challenge is 
to maintain the momentum gained 
in the past few years, and expand the 
scope and role of evidence synthesis to 
outcomes that go beyond conventional 
diagnostic accuracy. These outcomes 
include: accuracy of diagnostic 
algorithms (rather than single tests) 
and their relative contributions to the 
health care system; incremental or 
added value of new tests; impact of new 
tests on clinical decision-making and 
therapeutic choices; cost-effectiveness in 
routine programmatic settings; impact 
on patient-centered outcomes; and 
societal impact of new tools. Indeed, the 
GRADE (Grading of Recommendations 
Assessment, Development and 
Evaluation) approach to grading the 
quality of evidence and strength of 
recommendations for diagnostic tests 
recognizes that diagnostic accuracy 
results are surrogates for patient-
centered outcomes, and emphasizes 
that diagnostic tests are of value only if 
they result in improved outcomes for 
patients [61].
In addition to expanding the 
scope of evidence synthesis, it is also 
important to ensure that systematic 
reviews stay current by including new 
literature. Periodic updates are needed 
to ensure that systematic reviews 
provide the most current evidence 
available for clinical and policy 
decisions. For example, the literature 
on IGRAs has exploded in the past few 
years, and this necessitated an updated 
meta-analysis on this topic [37].
Recognizing the growing importance 
of evidence-based TB diagnosis 
and policy making, the Stop TB 
Partnership’s New Diagnostics Working 
Group has recently created a new 
subgroup on Evidence Synthesis for 
TB Diagnostics [62]. This subgroup 
will support the development of 
new systematic reviews, facilitate 
the development and dissemination 
of evidence summaries on new 
diagnostics, and actively promote 
their use in guideline and policy 
development processes, along the lines 
of the GRADE approach.  
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